Bullish Case: HIMS is 13% below a month ago but sits near both Helium's and the market's densest probability mass (25.5–26.5), mean reversion is the dominant historical pattern, and call volume exceeds puts by 32% with bullish risk +4%. The White House peptide-compounding proposal (Leerink's ~$440M potential HIMS revenue) remains an unfired catalyst, and heavy short interest offers squeeze optionality if OMB clearance lands.

Bearish Case: The term structure is sharply backwardated—market IV 103.8% Nov 7 and 126.8% Nov 14 vs ~80% by February—signaling imminent event risk (earnings + peptide ruling) that the market prices as likelier bad than good. Stock fell 13% in a month, FTC/Utah litigation is unresolved, and the market density holds fat downside tails at $18–24 that Helium underweights.

Potential Outcomes:

1. Post-event relief bounce, $27–31 (30%) — IV crush after Nov 14; falsifiable by IV collapsing below 90% with spot holding $25+.
2. Disappointment selloff, $21–25 (35%) — weak guidance or peptide delay/deferral; market density peaks near $25.5 but thickens at $22–24.
3. Peptide/OMB approval rally, $30–35 (15%) — falsifiable by formal interim access policy publication.
4. Range grind $24–28 (15%) — catalyst-light mean reversion.
5. Macro/legal shock < $21 (5%) — SPY IV expansion or adverse court filing.

November 04, 2026